Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03053336
Other study ID # Dnr: 2016/2041-31/2
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 21, 2017
Est. completion date June 30, 2019

Study information

Verified date September 2020
Source Karolinska Institutet
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to investigate the effect of using new app-based technology to improve self-care, compared to usual care in patients with type 2 diabetes. The hypothesis is that the intervention, i.e. using the new technology, will have a greater positive effect on physical activity levels and outcomes of HbA1c than usual care.


Recruitment information / eligibility

Status Completed
Enrollment 181
Est. completion date June 30, 2019
Est. primary completion date June 30, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Have a diagnosis of type 2 diabetes

- 18 years of age or older

- Ability to communicate in Swedish

- Have and be able to use a smartphone

Exclusion Criteria:

- Not being able to walk

Study Design


Intervention

Behavioral:
App-technology to increase physical activity
Access to the smartphone-app during 12 weeks. A personal step goal is set for each individual in the app.

Locations

Country Name City State
Sweden Karolinska Institutet Stockholm

Sponsors (2)

Lead Sponsor Collaborator
Karolinska Institutet Stockholm County Council, Sweden

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in dietary habits assessed using a food frequency questionnaire Baseline and month 3, 6 and 12
Other Change in tobacco use habits (smoking and Swedish snuff use) Baseline and month 3, 6 and 12
Other Change in sleeping habits assessed using a 13 item questionnaire Baseline and month 3, 6 and 12
Other Change in perceived purpose in life Baseline and month 3, 6 and 12
Other Change in perceived stress levels using the perceived stress scale Baseline and month 3, 6 and 12
Other Change in reported self-efficacy for exercise One's confidence in walking is assessed Baseline and month 3, 6 and 12
Other Change in reported self-efficacy diabetes is assessed using a 20 item questionnaire Baseline and month 3, 6 and 12
Other Change in RAND-36 Baseline and month 3, 6 and 12
Other Change in neighborhood Environment assessed by questions on safety and walking environment Baseline and month 3, 6 and 12
Other Social support for exercise assessed using a 6 item questionnaire Baseline and month 3, 6 and 12
Primary Change in physical activity level (counts/min from accelerometers) baseline and month 3, 6 and 12
Secondary HbA1c (mmol/mol) Baseline and month 3, 6 and 12
Secondary Steps/day Baseline and month 3, 6 and 12
Secondary Total cholesterol (mmol/L) Baseline and month 3, 6 and 12
Secondary HDL-cholesterol (mmol/L) Baseline and month 3, 6 and 12
Secondary Triglycerides (mmol/L) Baseline and month 3, 6 and 12
Secondary Apolipoprotein A1 (g/l) Baseline and month 3, 6 and 12
Secondary Apolipoprotein B (g/l) Baseline and month 3, 6 and 12
Secondary Body weight (kg) Baseline and month 3, 6 and 12
Secondary Body Mass Index (BMI, kg/m2) Baseline and month 3, 6 and 12
Secondary Body composition Including: %Body Fat, Fat free mass (kg), Muscle mass (kg), Total body water (kg, %) Baseline and month 3, 6 and 12
Secondary Waist circumference (cm) Baseline and month 3, 6 and 12
Secondary Blood pressure (mmHg) Baseline and month 3, 6 and 12
See also
  Status Clinical Trial Phase
Completed NCT02771093 - An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus Phase 4
Completed NCT02545842 - Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL) Phase 4
Recruiting NCT03436212 - Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump. N/A
Completed NCT03244800 - A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus. Phase 2
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Withdrawn NCT02769091 - A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes Phase 2
Recruiting NCT06065540 - A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor Phase 3
Recruiting NCT05008276 - Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Completed NCT04091373 - A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide Phase 1
Completed NCT03296800 - Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects Phase 1
Recruiting NCT06212778 - Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
Completed NCT05979519 - Fresh Carts for Mom's to Improve Food Security and Glucose Management N/A
Recruiting NCT05579314 - XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Terminated NCT03684642 - Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Phase 3
Completed NCT03248401 - Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes Phase 4
Completed NCT03644134 - A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns N/A
Completed NCT05295160 - Fasting-Associated Immune-metabolic Remission of Diabetes N/A
Completed NCT02836873 - Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment Phase 3
Completed NCT02252224 - Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance